Peer-influenced content. Sources you trust. No registration required. This is HCN.

FDA Approves Phesgo, At-home Treatment Regimen for Breast Cancer

According to the FDA, Phesgo — the combination of pertuzumab, trastuzumab and hyaluronidase-zzxf – is initially used in combination with chemotherapy and then can be administered subcutaneously at home by a health care professional after completion of chemotherapy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form